fbpx
Connect with us

BUSINESS

Medmen Enterprises Inc (OTCMKTS:MMNFF) Updates On Equity Financing Deal

Published

on

Medmen Enterprises Inc (OTCMKTS:MMNFF) has finalized a letter of engagement with entity named as Eight Capital. As per this deal, Eight Capital will purchase, together with Cormark Securities Inc. and a syndicate of underwriters, around 13.63 million units of the firm on a bought deal basis at a price a unit of CAD$5.50 for gross proceeds of around CAD$75 million. The deal is subject to custom approval regulations.

The buzz

Medmen reported that it plans to use the net proceeds from this offering for expansion of its retail presence across distinct cannabis markets, advancement of its production and grow facilities, general corporate and working capital purposes. The company has 19 licensed facilities spread across New York, Nevada and California. More recently, the company reported the acquisition of a Florida license. Medmen reported that the offering is scheduled to be closed on or about September 28, 2018.

In the month of July, Medmen Enterprises secured prime retail sites with long term leases in Miami Beach, Ft. Lauderdale, St. Petersburg, Key West and West Palm Beach. The firm continues to expand its presence in leading retail districts with heavy foot traffic and high visibility.

In other developments, Medmen Enterprises reported that it has closed the deal it reported in the month of June, linked to buying a dispensary and grow license, and related assets from Treadwell Nursery.

The License allows the firm to open 30 medical marijuana dispensaries in Florida and to carry out grow, delivery and manufacturing activities in the State of Florida. Under this deal, the company has also bought Treadwell Nursery’s grow facility situated near Orlando. This permit is one of exclusive 14 licenses in the state. Adam Bierman, the CEO and Co-founder of Medmen, stated that their entry into Florida via this deal showcases their expanding national footprint and their ability to execute.

BUSINESS

Real Brands Inc (OTCMKTS:RLBD) Signs An LOI To Purchase Proprietary CBD Formulas From Florida Based Integrative Medicine US

Published

on

Real Brands Inc (OTCMKTS:RLBD) has signed an LOI to buy proprietary CBD formulas of Integrative Medicine US. The formulas comprise ancient Chinese Medicine and Herbal Remedies that are blended CBD, nutrients, and endocannabinoid systems. Following the acquisition, Real Brands will use the formulas in its CBD Pharmacy brand. The company will use the new logo with a Chinese Symbol of healing.

CBD Pharmacy products

The initial product launch of CBD Pharmacy comprise salves, tinctures, balms, powders, and capsules developed to treat pain and promote relaxation, and boost immunity and energy.

Jerry Pearring, Chief Executive Officer of Real Brands, said medicinal herbs, CBD, and vitamins are blended using a proprietary formula to develop innovative medicine by Jonathan M. Fields, the founder of Integrative Medicine. The new products will help to keep the Real Brands in the driver’s seat to create a strong brand for CBD Pharmacy.

According to Pearring, CBD Pharmacy is expected to satisfy the growing consumer demand for hemp derived cannabidiol products. Consumers will also enjoy the benefits of eastern medical therapies.

Jonathan said the recent technological advances helped the company to develop superior medicinal products. Its features include Vegan, 100% Non-GMO, and tested in a third-party lab using cannabidiol. The company developed delivery mechanisms so that customers can get CBD and other ingredients in the right dosage to provide the desired effect for long-time.

Partners with Scot Piercy

Real Brands has partnered with Scot Piercy, a professional athlete, in April 2019. He will act as an ambassador for Real Brands Team and invested in the company last month. Pearring commenting the partnership said the company is excited to announce Scot as an ambassador. The investment shows the belief in the business model of the company and the long-term prospects. Pearring is pleased to welcome Scot on board Real Brands.

Piercy said he is proud to join the team of Real Brands. He studied about Real Brands and provides the support to grow hemp derived cannabidiol brands. Piercy further said it is looking forward to work with the company to introduce unique brands of Real Brands through e-commerce sites and retail channels.

Continue Reading

BUSINESS

Hexo Corp (NYSEAMERICAN:HEXO) Acquisition Of Newstrike Brands Finalized

Published

on

Acquisition now Finalized

Hexo Corp (NYSEAMERICAN:HEXO) has announced that it has completed the acquisition of all of Newstrike Brands’ issued and outstanding securities totaling 558,971, 064 marking the finalization of the acquisition process. The company has also received regulatory approval from relevant authorities including the high court further stamping the deal.

Reportedly, Newstrike Brands’ board of directors voted enthusiastically in favor of the acquisition that saw each of Newstrike’s stock exchanged for 0.06332 of Hexo’s share. Following the completion of the acquisition process, is expected to be delisted from TSX exchange platform as it will now operate under its new owner- Hexo.

Increased Production Space and Capacity

Popular voices in the industry believe that the $263 million acquisition sets Hexo among the industry’s elite. Among the several befits Hexo stands to gain from the acquisition includes additional production space estimated at 470,000 sqft. This is a significant addition to the company’s existing 1.3 million sqft.

With additional growing space comes increased production capacity. It is estimated that Hexo’s annual production capacity will surge from the current 110,000 kilos annually to a whopping 150,000 kilos annually which obviously translates to revenue influx.

Hexo’s CEO, Sebastien St-Louis said that “The combination of these two talented teams, both pioneers in the cannabis industry, will accelerate Hexo’s vision of creating the best cannabis technology company.” He adds that the Hexo is now commencing journey on the next phase of its progress.

The acquisition enhances the company’s solid position in the Canadian cannabis space and opening it up to countless possibilities abroad. The company already announced plans to set up operation in Greece as it seeks to seize the upcoming European market. Plans are also underway to set up operations in South America, the U.S (which is expected to open up fully by 2020), and more other locations.

The company already adjusted its 2020 revenue outlook to an optimistic $400 million. This projection factors in the company’s now bigger size in terms of production capacity and market access considering Hexo now assumes Newstrike’s distribution agreements with strategic partners across 8 Canadian provinces.

Continue Reading

BUSINESS

Synthetic MMJ Versus the Real Stuff

Published

on

CBD

When we use the term medical marijuana, we are referring to the entire unprocessed cannabis plant or its extracts for use as a pharmacological input in a treatment regime for individuals suffering from a variety of different health conditions. It may interest you to know that medical marijuana, at this point, only has explicit FDA approval as a safe and effective treatment for two conditions, both of which are severe and rare forms of epilepsy. Both of these conditions involve severe seizures and both of them represent conditions that no other pharmaceutical solution has been able to treat.

The established pharmaceutical version of medical marijuana that is used to treat these conditions is known as Epidiolex. This medication contains a pure form of CBD, and the FDA gave this approval in June 2018. Note it is also important to understand that the FDA has approved medications containing a synthetic version of THC known as Marinol and Cesamet. These drugs are used to treat nausea in people who are undergoing treatments for cancer and HIV. Interestingly, the FDA has not approved any marijuana-based drugs for the treatment of chronic or acute pain.

Synthetic versions of marijuana are often referred to as “Spice” or “K2”. According to the National Institute on drug abuse, synthetic marijuana is not considered marijuana. It is also not considered safe and is not recommended for any purpose. The important point to understand here is that synthetic marijuana attempts through chemical means to reproduce the essential function of marijuana as it interacts with human physiology. This runs up against what is known as the entourage effect – the idea that all of the elements of the cannabis plant work together in ways that supersede the impacts of just CBD or THC working alone.

Seen from this perspective, synthetic marijuana may not be nearly as effective and may have additional side effects that are difficult to account for.

Continue Reading
Advertisement
Advertisement
Advertisement






Trending Stories